{"id":"sglt2i-metformin-cofrogliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney to promote urinary glucose excretion. Metformin reduces hepatic gluconeogenesis and improves insulin sensitivity. Cofrogliptin, a DPP-4 inhibitor, increases incretin levels to stimulate glucose-dependent insulin secretion. The combination addresses multiple pathophysiologic defects in type 2 diabetes.","oneSentence":"This triple-combination therapy reduces blood glucose by inhibiting renal glucose reabsorption (SGLT2i), decreasing hepatic glucose production (metformin), and enhancing insulin secretion (DPP-4 inhibitor cofrogliptin).","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:07:43.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07019012","phase":"PHASE4","title":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-07-30","conditions":"T2DM","enrollment":170},{"nctId":"NCT06863532","phase":"NA","title":"Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-30","conditions":"Type 2 Diabetes","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SGLT2i+Metformin+Cofrogliptin","genericName":"SGLT2i+Metformin+Cofrogliptin","companyName":"Huazhong University of Science and Technology","companyId":"huazhong-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination therapy reduces blood glucose by inhibiting renal glucose reabsorption (SGLT2i), decreasing hepatic glucose production (metformin), and enhancing insulin secretion (DPP-4 inhibitor cofrogliptin). Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}